GlassScriptPhysician profile
Stephanie Baum
NPI 1609540335
$756.03
in general payments reported to CMS, 2019-2025
19 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $127 · 2022: $39.56 · 2023: $34.42 · 2024: $344 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $589.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $201.56 | 2022-2025 | Nucala, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $64.99 | 2021 | |
| Karyopharm Therapeutics INC. | $63.40 | 2021-2025 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $54.20 | 2022-2024 | Lynparza, Calquence |
| Argenx US, INC. | $52.86 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Incyte Corporation | $38.00 | 2025 | Monjuvi, Zynyz |
| Daiichi Sankyo INC. | $35.85 | 2025 | Vanflyta, Enhertu |
| Abbvie INC. | $32.78 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $27.15 | 2022-2023 | |
| Stemline Therapeutics INC. | $26.27 | 2024 | Orserdu |
| Merck Sharp & Dohme LLC | $21.55 | 2024 | Welireg, Keytruda |
| Novartis Pharmaceuticals Corporation | $20.20 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $19.18 | 2025 | Libtayo |
| Servier Pharmaceuticals LLC | $18.42 | 2024 | |
| Pharmacosmos Therapeutics INC. | $17.39 | 2025 | Monoferric |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $17.04 | 2024 | |
| Eisai INC. | $16.05 | 2025 | |
| Genentech USA, INC. | $15.26 | 2024 | Ocrevus |
| Genzyme Corporation | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Baum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.